Gene Genetic Technologies Ltd Says Plans Continue To Be Focussed On Concierge Medicine Groups And Gaining Coverage From US Payer System
Gene Genetic Technologies Ltd Says Plans Continue To Be Focussed On Concierge Medicine Groups And Gaining Coverage From US Payer System
基因遺傳技術有限公司表示，計劃繼續專注於禮賓醫學組和獲得覆蓋範圍從美國付款人系統
Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG", "GENE")), a global leader in guideline driven genomics-based tests in health, wellness and serious disease, is pleased to report excellent commercial progress in the USA strategic operations with the following updates:
Genetic Technologies Limited(澳大利亞證券交易所股票代碼：GTG，納斯達克代碼：GENE，“公司”，“GTG”，“GENE”)是健康、健康和嚴重疾病方面以指南為基礎的基因組學檢測的全球領先企業，該公司高興地報告了美國戰略業務的出色商業進展，最新情況如下：
Strategic Highlights:
戰略要點：
Active engagement with 11 US payer groups with an initial target list of 30 with coverage in tens of millions of lives
Engagement with 19 US Concierge Medicine Practices with large volume pricing discussions
Commercial evaluations underway at 10 US medical/family practices
Re-engagement with 1,600 previous geneType US customers
Dr Erika Spaeth, a key presenter at the Precision Medicine Leaders...
與11個美國付款人團體積極接觸，最初的目標名單為30個，覆蓋數千萬人的生活
與19家美國禮賓醫療診所進行大批量定價...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。